Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary J Noel

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|November 15, 2007
Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacinTodd A Davies, Eugene Leibovitz, Gary J Noel, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Effects of three fluoroquinolones on QT interval in healthy adults after single dosesGary J Noel, Jaya Natarajan, Shuchean Chien, et al.
The Pediatric Infectious Disease Journal|September 29, 2007
Comparative study of levofloxacin in the treatment of children with community-acquired pneumoniaJohn S Bradley, Adriano Arguedas, Jeffrey L Blumer, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2009
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsHolly Kimko, Xu Xu, Partha Nandy, et al.
Pharmacoepidemiology and Drug Safety|February 4, 2006
Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care populationJohn D Seeger, William A West, Daniel Fife, et al.
The Pediatric Infectious Disease Journal|November 30, 2006
An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis mediaAdriano Arguedas, Ron Dagan, Michael Pichichero, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United StatesJames A Karlowsky, Clyde Thornsberry, Ian A Critchley, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey of investigatorsAmy Corneli, Chris Wheeler, John Bradley, et al.
Pediatrics|June 12, 2014
Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacinJohn S Bradley, Ralph E Kauffman, Dainius A Balis, et al.
Antimicrobial Agents and Chemotherapy|March 28, 2007
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsThomas P Lodise, Rienk Pypstra, James B Kahn, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|November 15, 2007
Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacinTodd A Davies, Eugene Leibovitz, Gary J Noel, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Effects of three fluoroquinolones on QT interval in healthy adults after single dosesGary J Noel, Jaya Natarajan, Shuchean Chien, et al.
The Pediatric Infectious Disease Journal|September 29, 2007
Comparative study of levofloxacin in the treatment of children with community-acquired pneumoniaJohn S Bradley, Adriano Arguedas, Jeffrey L Blumer, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2009
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsHolly Kimko, Xu Xu, Partha Nandy, et al.
Pharmacoepidemiology and Drug Safety|February 4, 2006
Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care populationJohn D Seeger, William A West, Daniel Fife, et al.
The Pediatric Infectious Disease Journal|November 30, 2006
An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis mediaAdriano Arguedas, Ron Dagan, Michael Pichichero, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United StatesJames A Karlowsky, Clyde Thornsberry, Ian A Critchley, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey of investigatorsAmy Corneli, Chris Wheeler, John Bradley, et al.
Pediatrics|June 12, 2014
Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacinJohn S Bradley, Ralph E Kauffman, Dainius A Balis, et al.
Antimicrobial Agents and Chemotherapy|March 28, 2007
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsThomas P Lodise, Rienk Pypstra, James B Kahn, et al.
Pageof 3